|Updates in MDS: A Special Edition on Higher-risk Disease|
Mikkael S. Sekeres, MD, MS
|Release Date: April 21, 2021|
Expiration Date: April 21, 2022
In this activity, Dr. Sekeres will discuss the current and future treatment landscape for higher-risk MDS. He will provide advice for distinguishing higher-risk MDS from lower-risk MDS, review appropriate treatment goals, and outline current treatment algorithms for higher-risk disease. He will also outline exciting advances in the treatment and management of higher-risk MDS, including a review of the data on the NEDD8 inhibitor pevonedistat, APR 246 targeting TP53-mutations and novel combinations.Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
|Begin, Earn CreditView Only, No Credit|